Cryoport, Inc. · NASDAQ:CYRX

Cryoport — Q4 2025 Earnings Presentation

34 slides from Cryoport's earnings presentation, Mar 3, 2026

  1. Slide 1: Q4 FY-2025 Earnings Call

    Q4 FY-2025 Earnings Call (o) Enabling the Future of Medicine

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Statements in this presentation which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans, or predictions of the future, are forward-looking statements within the meaning of the

  3. Slide 3: Cryoport Snapshot – By the Numbers

    Cryoport Snapshot – By the Numbers Leading integrated platform ensuring the integrity of critical biomaterials across the life sciences value chain © 2026 CRYOPORT, INC. 3

  4. Slide 4: The Cryoport Platform: Services & Products

    The Cryoport Platform: Services & Products Core services and products supporting the management of critical biomaterials © 2026 CRYOPORT, INC. 4

  5. Slide 5: Cryoport Snapshot – Revenue Mix

    Cryoport Snapshot – Revenue Mix Leading integrated platform ensuring the integrity of critical biomaterials across the life sciences value chain © 2026 CRYOPORT, INC. 5

  6. Slide 6: Serving The High Growth $10B+ CGT Market

    Serving The High Growth $10B+ CGT Market Expanding pipeline, rising trial activity, and growing patient populations underpin durable growth opportunities for Cryoport © 2026 CRYOPORT, INC. 6

  7. Slide 7: 2025 Revenue Drivers

    2025 Revenue Drivers © 2026 CRYOPORT, INC. 7

  8. Slide 8: Revenue Q4-FY2025

    Revenue Q4-FY2025 © 2026 CRYOPORT, INC. 8

  9. Slide 9: Driving Bottom-Line Improvement in Q4 2025

    Driving Bottom-Line Improvement in Q4 2025 with a Strong Balance Sheet to Support Long-term Strategy © 2026 CRYOPORT, INC. 9

  10. Slide 10: Life Science Services Key Revenue Growth Drivers

    Life Science Services Key Revenue Growth Drivers Commercial CGT Revenue Clinical Trial Revenue ($ in millions) ($ in millions) +16% YoY —— Q4 2025 Q4 2024 Q4 2025 ©2026 CRYOPORT, INC. 10

  11. Slide 11: FY-25 Life Sciences Services Overview

    FY-25 Life Sciences Services Overview BioLogistics Revenue BioStorage/BioServices Revenue ($ in millions) ($ in millions) +22% YoY +17% YoY ©2026 CRYOPORT, INC. 1

  12. Slide 12: Clinical Trial and Commercial Revenue Trends

    Clinical Trial and Commercial Revenue Trends © 2026 CRYOPORT, INC. 12

  13. Slide 13: Patients First: Supporting the Therapies of Tomorrow

    Patients First: Supporting the Therapies of Tomorrow Clinical Trials Supported, by Trial Phase = Phase! m Phasell m Phase Ill 760 675 ge) - 602 528 82 i) 14 436 © =n 3a 364 25 ~ m3 ~ jsona cn WE 16 eyoncl SEB, strimvense | PECANS = 9 313 135 20 a ~ - ° ea FyRReOl ->yescarta_ Zemcelpro. ve" Sopa aner

  14. Slide 14: Cryoport - the Leading Service Provider for CGT

    Cryoport - the Leading Service Provider for CGT Deeply embedded with customers and partners with significant barriers to entry © 2026 CRYOPORT, INC. 14

  15. Slide 15: Growth Drivers

    Growth Drivers Strong foundation for sustainable growth and margin expansion © 2026 CRYOPORT, INC. 15

  16. Slide 16: Growing Clinical Trial Count

    Growing Clinical Trial Count Spring-loaded Pipeline for Commercial Revenue Growth © 2026 CRYOPORT, INC. 16

  17. Slide 17: Supporting Commercial Cell and Gene Therapies Globally

    Supporting 20 Commercial Cell and Gene Therapies Globally © 2026 CRYOPORT, INC. 17

  18. Slide 18: Gross Margins

    Gross Margins Q4-2025 and FY2025 © 2026 CRYOPORT, INC. 18

  19. Slide 19: Adjusted EBITDA

    Adjusted EBITDA © 2026 CRYOPORT, INC. 19

  20. Slide 20: Balance Sheet 12/31/2025

    Balance Sheet 12/31/2025 © 2026 CRYOPORT, INC. 20

  21. Slide 21: The Cryoport Platform: End-to-End Support

    The Cryoport Platform: End-to-End Support Comprehensive supply chain management of cell & gene therapies throughout the full workflow – upstream and downstream © 2026 CRYOPORT, INC. 21

  22. Slide 22: The Cryoport Platform: BioLogistics

    The Cryoport Platform: BioLogistics Leading provider of global temperature-controlled, compliant biomaterials handling, focused on cell & gene therapies © 2026 CRYOPORT, INC. 22

  23. Slide 23: The Cryoport Platform: IntegriCell

    The Cryoport Platform: IntegriCell® Manufacturing-ready leukopak and cryopreservation services and processes for cell therapy © 2026 CRYOPORT, INC. 23

  24. Slide 24: The Cryoport Platform: BioServices

    The Cryoport Platform: BioServices Centralized biomaterials storage, fulfillment, and related services for allogeneic and autologous cell & gene therapies © 2026 CRYOPORT, INC. 24

  25. Slide 25: The Cryoport Platform: BioStorage

    The Cryoport Platform: BioStorage Secure and compliant biorepository for longer-term, temperature-controlled storage © 2026 CRYOPORT, INC. 25

  26. Slide 26: The Cryoport Platform: Products

    The Cryoport Platform: Products Leading cryogenic systems manufacturer globally © 2026 CRYOPORT, INC. 26

  27. Slide 27: Advanced Integrated Digital Platform

    Advanced Integrated Digital Platform Advanced Integrated Digital Platform Proprietary digital infrastructure unifying services, equipment, data, and users into a single source for end-to-end visibility © 2026 CRYOPORT, INC. 27

  28. Slide 28: Regulatory Discipline and Compliance

    Regulatory Discipline and Compliance Assurance of global regulatory compliance © 2026 CRYOPORT, INC. 28

  29. Slide 29: Comprehensive Global Capabilities

    Comprehensive Global Capabilities © 2026 CRYOPORT, INC. 29

  30. Slide 30: Why Cryoport?

    Why Cryoport? Market leader in temperature-controlled supply chain services Scalable platform with expanding suite of integrated services Deeply embedded in majority of cell & gene clinical and commercial therapies Double-digit services revenue growth and stabilizing product revenue Significant marg

  31. Slide 31: Total Monthly Biopharma Funding

    Total Monthly Biopharma Funding » + Source: FactSet, UBS; Note: Includes Venture, IPOs, and equity follow-on; Data as of 1/31/2026 ©2026 CRYOPORT, INC. 31

  32. Slide 32: FDA Regulatory Shift Unlocks CAR-T Growth

    FDA Regulatory Shift Unlocks CAR-T Growth © 2026 CRYOPORT, INC. 32

  33. Slide 33: CAR-T Label Updates Accelerating Outpatient Trend

    CAR-T Label Updates Accelerating Outpatient Trend © 2026 CRYOPORT, INC. CONFIDENTIAL | 33

  34. Slide 34: Join us in “Enabling the Future of Medicine”

    Join us in “Enabling the Future of Medicine ” Jerrell Shelton Chief Executive Officer jshelton@cryoport.com https://www.cryoport.com/ https://ir.cryoportinc.com/

Cryoport — Q4 2025 Earnings Presentation on 6ix